Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial : The Lancet Oncology
Links shared publicly online about this topic.
- 542total visits
Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial : The Lancet Oncology
Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. By - Dr Johan Hansson MD, P...
View full resource at thelancet.com
Tags: Hepatitis B Medication, Hepatitis C Medication, Cancer, Skin Cancer, Melanoma, Phase 3 Clinical Trial, Intron A
Most Recently Shared on January 31, 2011 at 2:36 am By:
[Articles] Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients wit... http://bit.ly/iiQbTv
Advertisement
